231 related articles for article (PubMed ID: 812544)
21. [Production and experimental testing of the polyvalency of corpuscular vaccine for the prevention of Pseudomonas aeruginosa infections II. Experimental testing of the immunogenicity of polyvalent corpuscular Pseudomonas aeruginosa vaccine].
Moroz AF; Antsiferova NG; Radkevich SA; Mishina VS
Zh Mikrobiol Epidemiol Immunobiol; 1981 Oct; (10):74-80. PubMed ID: 6800165
[TBL] [Abstract][Full Text] [Related]
22. Specificity of the protective response induced by the slime layer of Pseudomonas aeruginosa.
Mates A; Zand P
J Hyg (Lond); 1974 Aug; 73(1):75-84. PubMed ID: 4213979
[TBL] [Abstract][Full Text] [Related]
23. Investigations on the efficacy of monovalent Pseudomonas aeruginosa vaccine for oral administration in Pseudomonas aeruginosa experimental infection.
Meitert E; Sima F; Savulian C; Petrovici M; Chersulick E; Costache G
Arch Roum Pathol Exp Microbiol; 1989; 48(3):237-51. PubMed ID: 2519634
[TBL] [Abstract][Full Text] [Related]
24. Immunological evaluation of OMP-F of native Iranian Pseudomonas aeruginosa as a protective vaccine.
Ahmadi H; Tabaraie B; Maleknia S; Pormirzagholi F; Nejati M; Hedayati MH
J Infect Dev Ctries; 2012 Oct; 6(10):721-6. PubMed ID: 23103894
[TBL] [Abstract][Full Text] [Related]
25. Immunization of burn-patients with a Pseudomonas aeruginosa outer membrane protein vaccine elicits antibodies with protective efficacy.
Lee NG; Jung SB; Ahn BY; Kim YH; Kim JJ; Kim DK; Kim IS; Yoon SM; Nam SW; Kim HS; Park WJ
Vaccine; 2000 Mar; 18(18):1952-61. PubMed ID: 10699346
[TBL] [Abstract][Full Text] [Related]
26. [Use of polyvalent vaccine against Pseudomonas aeruginosa in extensive burns].
Nasiłowski W; Zietkiewicz W; Brudzyńska-Charewicz S; Bukowska D; Serafińska D; Rudowski W
Pol Tyg Lek; 1981 Aug; 36(32):1207-11. PubMed ID: 6798556
[No Abstract] [Full Text] [Related]
27. A new polyvalent Pseudomonas vaccine.
Miler JM; Spilsbury JF; Jones RJ; Roe EA; Lowbury EJ
J Med Microbiol; 1977 Feb; 10(1):19-27. PubMed ID: 402473
[TBL] [Abstract][Full Text] [Related]
28. A new Pseudomonas vaccine: preliminary trial on human volunteers.
Jones RJ; Roe EA; Lowbury EJ; Miler JJ; Spilsbury JF
J Hyg (Lond); 1976 Jun; 76(3):429-39. PubMed ID: 819576
[TBL] [Abstract][Full Text] [Related]
29. Multivalent DNA vaccine protects mice against pulmonary infection caused by Pseudomonas aeruginosa.
Saha S; Takeshita F; Sasaki S; Matsuda T; Tanaka T; Tozuka M; Takase K; Matsumoto T; Okuda K; Ishii N; Yamaguchi K; Klinman DM; Xin KQ; Okuda K
Vaccine; 2006 Sep; 24(37-39):6240-9. PubMed ID: 16806598
[TBL] [Abstract][Full Text] [Related]
30. OprF/I-vaccinated sera inhibit binding of human interferon-gamma to Pseudomonas aeruginosa.
Ding B; von Specht BU; Li Y
Vaccine; 2010 Jun; 28(25):4119-22. PubMed ID: 20433804
[TBL] [Abstract][Full Text] [Related]
31. Mouse-protection experience with monovalent Pseudomonas aeruginosa vaccine.
Sourek J; Výmola F; Zelenková L
Zentralbl Bakteriol A; 1980 Mar; 246(3):353-62. PubMed ID: 6775443
[TBL] [Abstract][Full Text] [Related]
32. Passive anti-PcrV treatment protects burned mice against Pseudomonas aeruginosa challenge.
Neely AN; Holder IA; Wiener-Kronish JP; Sawa T
Burns; 2005 Mar; 31(2):153-8. PubMed ID: 15683685
[TBL] [Abstract][Full Text] [Related]
33. Passive protective properties of serum fractions from mice inoculated with an anti-pseudomonas vaccine.
Jones RJ; Hall M; Ricketts CR
Immunology; 1972 Dec; 23(6):889-95. PubMed ID: 4630781
[TBL] [Abstract][Full Text] [Related]
34. [Morphological study of the organs and tissues of mice infected after a burn with a Pseudomonas aeruginosa strain and treated with a Pseudomonas aeruginosa polyvalent corpuscular vaccine and tobramycin].
Moroz AF; Kharitonova AM; Chanturiia TsK
Antibiotiki; 1983 May; 28(5):341-5. PubMed ID: 6410985
[TBL] [Abstract][Full Text] [Related]
35. Some biological and immunological properties of extracellular slime from Pseudomonas aeruginosa.
Maresz-Babczyszyn J; Sokalska M
Arch Immunol Ther Exp (Warsz); 1978; 26(1-6):255-60. PubMed ID: 107919
[TBL] [Abstract][Full Text] [Related]
36. Effects of elastase, protease and common antigen (OEP) from Pseudomonas aeruginosa on protection against burns in mice.
Kawaharajo K; Homma JY
Jpn J Exp Med; 1977 Dec; 47(6):495-500. PubMed ID: 416253
[TBL] [Abstract][Full Text] [Related]
37. Preparation and assay of horse anti-Pseudomonas serum and -globulin in mice.
Laborde HF; De Fajardo CL
Prog Immunobiol Stand; 1971; 5():419-24. PubMed ID: 4633969
[No Abstract] [Full Text] [Related]
38. Protective characteristics of the antigen common to Pseudomonas and Vibrio and significance of bacterial endotoxins in protection against selected bacterial infections.
Sourek J
Zentralbl Bakteriol Mikrobiol Hyg A; 1985 Jul; 259(4):538-47. PubMed ID: 2413656
[TBL] [Abstract][Full Text] [Related]
39. [Results of using a polyvalent vaccine against Pseudomonas aeruginosa in patients with burns treated at various therapeutic centers in Poland].
Bukowska D; Serafińska D; Zietkiewicz W; Rudowski W; Hoffman S; Uszyński H; Molski M; Hess C; Jonecko A; Popiel D
Pol Tyg Lek; 1986 Dec; 41(49):1549-52. PubMed ID: 3108869
[No Abstract] [Full Text] [Related]
40. [An acellular vaccine from Pseudomonas aeruginosa. II. -- Estimate of immuneserum protective effect by measure of bacterial clearance (author's transl)].
Daoulas-Le Bourdelles F; Berche P; Véron M
Ann Microbiol (Paris); 1977 Jul; 128B(1):61-71. PubMed ID: 410340
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
